Gemini Health Partners Launches AI Advisory for High-Cost Specialties

HOUSTON, Oct. 7, 2026 /CourierPR/ -- Houston-based healthcare revenue cycle management firm Gemini Health Partners has announced the expansion of its services into the advisory market, specifically focusing on artificial intelligence (AI) strategy for high-cost specialty revenue cycle management (RCM). The new offering is designed to assist private specialty clinics, hospitals, and health systems in determining where AI and automation can address revenue cycle challenges, how technology should integrate with existing operations, and how results should be measured. Organizations can engage Gemini for assessment and strategic guidance without outsourcing their billing department.

The announcement comes as healthcare organizations grapple with the complexities of managing high-cost specialty services, such as proton therapy, radiopharmaceutical therapy, and advanced imaging services. These services often involve intricate authorization workflows, complex drug reimbursement reviews, and rigorous medical necessity checks. The challenges are compounded by the high cost and variability of payer reimbursements, which can significantly impact an organization's financial performance.

Christopher Gonzalez, the CEO of Gemini Health Partners, emphasized the importance of starting an AI strategy for specialty revenue cycle management with a clear understanding of how care is authorized, billed, and paid.

The advisory service offered by Gemini Health Partners combines specialty operating experience with real adjudicated claims and prior authorization data across high-cost specialties. This unique data set, spanning procedures like proton therapy, radiation therapy, radiopharmaceutical therapy, medical oncology drug reimbursement, radiology procedures, MRI and PET scans, urology, and orthopedics, provides a depth of procedure-level detail that is uncommon in the revenue cycle management industry. The data covers complex cases from initial authorization submissions to payer criteria applied, denials, and their stated reasons, as well as outcomes from appeals and final payment behavior.

Gemini Health Partners' approach to AI strategy engagements includes assessing data quality, workflow constraints, and current systems, before prioritizing use cases such as authorization workflows for complex radiation therapies and oncology drug reimbursement review, MRI and PET imaging medical-necessity checks, and denial management. The firm develops claims-informed business cases with explicit assumptions, supports technology architecture, vendor evaluation, governance, and phased implementation, and includes performance measures such as denial rates, authorization turnaround, and cost to collect.

The advisory service also provides feasibility analysis for new clinical investments, such as radiopharmaceutical therapy programs, PET and advanced imaging services, medical oncology program expansion, urology, and new specialty centers.

This new advisory offering marks Gemini Health Partners' expansion into the healthcare advisory market, providing a dedicated focus on AI strategy for high-cost specialty revenue cycle management. The firm's services span specialty RCM AI strategy, revenue cycle assessment, new-program feasibility, technology architecture and implementation support, prior authorization, and end-to-end revenue cycle operations. The company's services are designed to help healthcare organizations navigate the complexities of managing high-cost specialty services, including the challenges of authorization, billing, and payment, while leveraging AI and automation to improve efficiency and financial performance.